PEAR THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR EVENT HOSTED BY CREDIT SUISSE
BOSTON–(BUSINESS WIRE)–Apr. 5, 2022– (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced management will participate in the following upcoming virtual investor conferences in April 2022.
- Chardan Prescription Digital Therapeutics Summit. Corey McCann, MD, PhD, President and CEO, will participate in a fireside chat on Monday, April 11 at 1:00 p.m. Eastern Time. A live webcast can be accessed by clicking and will be made available in the Investors section of the company’s website at . To learn more about the summit please contact .
- 21st Annual Needham Virtual Healthcare Conference. Chris Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will present on Tuesday, April 12 at 11:00 a.m. Eastern Time. A live webcast can be accessed by clicking and will be made available in the Investors section of the company’s website at .
A replay of the conference webcasts will be available on the company’s website for up to 30 days following the live presentations.
About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at .
Source: Pear Therapeutics, Inc.Back